The subthalamic nucleus (STN) receives a dopaminergic innervation from the substantia nigra pars 30 compacta, but the role of this projection remains poorly understood, particularly in primates. To address 31 this issue, we used immuno-electron microscopy to localize D1, D2, and D5 dopamine receptors in the 32 STN of rhesus macaques, and studied the electrophysiological effects of activating D1-like or D2-like 33 receptors in normal and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine ( 
INTRODUCTION 51
The subthalamic nucleus (STN) is the only glutamatergic structure in the basal ganglia circuitry, 52 and its activity is profoundly altered in Parkinson's disease (PD) (Galvan and Wichmann 2008) . The STN 53 receives GABAergic projections from the external segment of the globus pallidus (GPe) and 54 glutamatergic inputs from the cerebral cortex, thalamus and brainstem (Joel and Weiner 1997; Mathai 55 and Smith 2011). It has traditionally been assumed that PD-associated changes of STN activity result 56 from degeneration of the dopaminergic nigrostriatal tract, and the resultant loss of striatal dopamine. 57
However, both the primate and rodent STN receive a modest dopaminergic innervation from the 58 substantia nigra compacta (SNc) ( In rats, dopamine is released in the STN in response to local electrical stimulation (Cragg et al. 77 2004). Although early in vivo studies suggested an inhibitory effect of dopamine on rat STN neurons 78 (Campbell et al. 1985; Hassani and Feger 1999) , recent in vitro data from rodent brain slices have 79 indicated that activation of D1-like receptors (specifically D5 receptors) increases burst firing in the STN 80 through a postsynaptic mechanism (Baufreton et al. 2003) , while activation of D2-like receptors 81
The animals were deeply anesthetized with an overdose of sodium pentobarbital (100 mg/kg, 111 i.v.) before being perfused with a mixture of paraformaldehyde (4%) and glutaraldehyde (0.1%) in 112 phosphate buffered saline (PBS, 0.01 M, pH 7.4). Brain blocks were cut in 60 μm-thick sections with a 113 vibrating microtome, collected in cold PBS and processed for immunohistochemistry as described below. 114
115

Primary antisera 116
We used brain sections from 7 monkeys for the immunolocalization of D1, D2 and D5 dopamine 117 receptors. For each receptor subtype, brain tissue from at least 3 of these 7 animals was used (STN 118 tissue from 2 monkeys was used for more than one receptor subtype immunolabeling). 119
To identify D1 and D5 receptors, two affinity-purified highly specific antibodies were used. 120
Although the transmembrane regions of D1 and D5 receptors are highly homologous, these receptors 121 differ significantly at the third intracellular loop and carboxy-terminus (Sunahara et al. 1991; Tiberi et al. 122
1991). We used highly specific monoclonal D1 receptor antibodies (1 : 500; Sigma-Aldrich, St Louis, MO, 123 USA; D-187), which were raised in rats against a 97-amino acid peptide in the carboxy-terminus. These 124 antibodies have been extensively used and well characterized, in both rodents and primates, using 125
Western immunoblot techniques, transfected cells and pre-absorption control experiments (Betarbet 126 and . Briefly, the immunoblot showed reactivity of a single polypeptide band of 133 47 kDa, the expected molecular weight of the D5 receptor based on cloning studies, in rat brain tissue 134 that was subsequently abolished by pre-absorption of the D5 receptor antibodies with a cognate 135 peptide. These D5 receptor antibodies were found to bind to recombinant cells that were transfected 136 with D5 complimentary DNA, while no immunoreactivity was observed in cells that expressed other 137 dopamine receptors (Khan et al. 2000) . 138
To identify D2 receptors, commercially available polyclonal antibodies to the D2 receptor 139 (Millipore, Billerica, MA; AB5084P) were used at a concentration of 1:1000. The D2 receptor antibodies 140 were raised in rabbits against a 28 amino acid peptide sequence of the third intracellular loop of the 141 human D2 receptor that is shared by both the long and short forms of the receptor. No significant 142 homology to other dopamine receptors (D1, D3, D4 or D5) has been reported for this peptide. returned to a decreasing gradient of cryoprotectant solutions, and rinsed in PBS. To block non-specific 153 binding sites, sections were pre-incubated for 1 hour at room temperature in PBS containing 10% 154 normal goat serum and 1% bovine serum albumin. This was followed by incubation in the primary 155 antibody solution containing 1% normal goat serum, 1% bovine serum albumin, and the D1, D2 or D5 156 receptor antibodies for 48 hours at 4°C. The incubation was terminated with several rinses in PBS. Then, 157 the sections were incubated in secondary biotinylated goat anti-rabbit (to reveal D2 or D5 receptors) or 158 anti-rat (to reveal D1 receptors) IgGs (1:200 dilution; Vector Laboratories, Burlingame, CA, USA) for 90 159 min. The sections were then rinsed again in PBS and incubated for 90 min with the avidin-biotin 160 peroxidase complex at a dilution of 1:100 (Vector Laboratories). Then, sections were washed in PBS and 161
Tris buffer (50 mM; pH 7.6) and transferred to a solution containing 0.025% 3,3′-diaminobenzidine 162 tetrahydrochloride (Sigma-Aldrich), 1 mM imidazole (Fisher Scientific, Waltham, MA) and 0.005% 163 hydrogen peroxide in Tris buffer for 10 min. Sections were then rinsed in PB (0.1 M, pH 7.4) and treated 164 with 1% OsO 4 for 20 min. Thereafter, the tissue was returned to PB and dehydrated with increasing 165 concentrations of ethanol. To increase the contrast of the tissue, 1% uranyl acetate was added to the 166 solution during the 35 min exposure to the 70% ethanol solution. After dehydration, sections were 167 treated with propylene oxide and embedded in epoxy resin for 12 hours (Durcupan ACM; Fluka, Buchs, 168 Switzerland), mounted onto slides, and placed in a 60°C oven for 48 hours. Tissue samples containing 169 the STN were mounted onto resin blocks with cyanoacrylate ester, and cut into 60 nm-thick ultrathin 170 sections with an ultramicrotome (Leica Ultracut T2; Nussloch, Germany). These sections were collected 171 on Pioloform-coated copper grids and stained with lead citrate for 5 min to enhance tissue contrast. 172
173
Quantitative ultrastructural analysis 174
Ultrathin sections were examined with an EM (Model 1011 JEOL, Tokyo, Japan, or model 175 EM10C, Zeiss, Oberkochen, Germany). Randomly selected areas containing immunoperoxidase labeling 176 were scanned and photographed at a magnification of 16,000-25,000X. Electron micrographs were 177 taken with a CCD camera (Dual View 300W; Gatan, Inc., Pleasanton, CA, USA) controlled by Digital 178
Micrograph software (Gatan, Inc.), and saved to computer disk. Some micrographs were later adjusted 179 for brightness and contrast with either Digital Micrograph or Adobe Photoshop. 180
Immunopositive elements were identified based on the presence of the electron dense 181 amorphous peroxidase reaction product, which was usually associated with the internal surface of the 182 plasma membrane (e.g., fig 1A) or the external surface of subcellular organelles (e.g., fig 1B ) parkinsonism. The degree of motor impairment was assessed every week. We rated motor behavior 223 with a parkinsonism rating scale that comprised gross motor activity, balance, posture, arm 224 bradykinesia, arm hypokinesia, leg bradykinesia, leg hypokinesia, arm tremor and leg tremor. Each item 225 was scored between 0 and 3 (normal to severe), for a maximum of 27 points. In addition, we used a cage 226 activity monitoring system based on infrared beams and a computer-assisted observation method. A 227 monkey was considered to be parkinsonian if the score in the parkinsonian rating scale was > 10, and if 228 the movement counts in the activity monitoring were < 60% from baseline (pre-MPTP treatment). We 229 have used these assessment methods extensively in the context of other studies (Galvan et al. 2010 ; 230
Wichmann et al. 2001). 231
The total amounts of MPTP administered were 22 mg/kg in one monkey and 32 mg/kg in the 232 other, and the treatment lasted (with interruptions) 16 and 17 months, respectively. The 233 electrophysiological studies did not begin until the animals were stably parkinsonian for a minimum of 6 234 weeks after the last MPTP injection (see also below). 235
236
Electrophysiological recordings 237
For the electrophysiological recording sessions, the animals were seated in a primate chair with 238 their heads restrained, but free to move their body and limbs. The animals remained awake during 239 these sessions, as judged by maintained eye opening and occasional movements. The dura was 240 perforated with a 21-gauge guide tube, and a tungsten microelectrode (Z = 0.3-1.0 MΩ at 1 kHz; FHC, 241
Bowdoinham, ME) was lowered into the brain with a microdrive (MO-95; Narishige, Tokyo, Japan). 242
Extracellular neuronal electrical signals were amplified (DAM-80 amplifier; WPI, Sarasota, FL), filtered 243 (400-6,000 Hz; Krohn-Hite, Brockton, MA), displayed on a digital oscilloscope (DL1540; Yokogawa, Tokyo, 244 Japan), and made audible via an audio amplifier. The neuronal signals were digitized at a sampling rate 245 of 25 kHz and stored onto computer disk using a data acquisition interface (Power1401; CED, 246
Cambridge, UK) and commercial software (Spike2, CED). 247
We identified the STN, based on characteristic electrophysiological features (including high 248 cellular density and persistent neuronal activity), its close proximity to fibers of the internal capsule, and 249 the location of the fast firing neurons of the substantia nigra reticulata (SNr) which are ventral to the 250
STN (Wichmann et al. 1994a). 251 252
Intracerebral injections 253
In order to examine the effects of activation of D1-like receptors (i.e., D1 or D5 receptors) or D2-254 like receptors (i.e., D2, D3 or D4 receptors) in the STN, agonists for these receptor subtypes were locally 255 injected into the STN, with concomitant recording of electrophysiologic activity in the vicinity of the 256 injection site. To accomplish these injections, we used a device that combines a regular tungsten 257 microelectrode with thin fused silica tubing (as described in detail in Kliem and Wichmann 2004). The 258 drugs were delivered using a microsyringe (CMA Microdyalisis, Kista, Sweden) mounted on an infusion 259 pump (Model 102, CMA). The pump was remotely controlled by computer. In each experiment, the 260 recording-injection device was positioned in the STN with a microdrive. Once in the STN area, the 261 injection/recording device was advanced slowly to identify isolated neuronal spikes, and the 262 spontaneous baseline firing of cells was recorded for at least 60 s. Then, the infusion pump was 263 activated and the recording session continued during the infusion of the drug (0.4 μl injected at a rate of 264 0.2 μl/min), and after the end of the infusion for as long as possible, while the amplitude of neuronal 265 spikes and quality of the recording remained constant. In some experiments, more than one injection 266 was done along the same injection system track. When more than one injection was done along the 267 same track, we kept a minimum dorso-ventral distance of 0.5 mm between injection sites, and 268 separated the injections by at least 30 min. 269
The D1-like receptor agonist SKF82958 (3 μg/μl) or the D2-like receptor agonist quinpirole (5 270 μg/μl, both drugs from Sigma-Aldrich) were dissolved in artificial cerebrospinal fluid (aCSF: 143 mM 271 NaCl, 2.8 mM KCl, 1.2 mM CaCl 2 , 1.2 mM MgCl 2 and 1 mM Na 2 HPO 4 ), at a final pH of 5.0 for SKF82958 272 and 7.0 for quinpirole. SKF82958 has a much higher affinity to D1-like than D2-like receptors 273 
Termination of the experiments and histological processing 281
At the conclusion of the electrophysiology experiments, the animals were deeply anesthetized, 282 perfused, and the brains were obtained and sectioned as described above. Sections containing the STN 283 were stained for Nissl substance to visualize electrode and injection system penetrations, while 284 alternate sections were immunolabeled for the neuronal marker microtubule associated protein 2 285 (mouse anti-MAP2, 1:1000, Millipore) to assess the extent of neuronal damage induced by the 286 electrode tracks. The expression of tyrosine hydroxylase (TH) was assessed with immunohistochemistry 287 (monoclonal mouse anti-TH antibody, 1: 1000, Millipore) to evaluate the degree of dopaminergic 288 denervation in the sensorimotor putamen in the two MPTP-treated animals. For comparison, we used 289 brain sections containing the post-commissural putamen from three other normal monkeys from our 290 tissue bank. These were processed simultaneously with the tissue from the MPTP-treated monkeys. 291
The labeling for MAP2 and TH were visualized using the immunoperoxidase method, as 292 described above, with the difference that the sodium borohydride and freezing steps were omitted and 293 0.1% Triton X-100 was added to all incubations. After revealing the MAP2 or TH antibodies, the sections 294 were mounted on gelatin-coated slides, dehydrated in alcohol, immersed in toluene and a coverslip was 295 applied with Cytoseal XYL (Richard-Allan Scientific, Kalamazoo, MI). The slides were digitized with an 296
Aperio Scanscope CS system (Aperio Technologies, Vista, CA). 
Analysis of electrophysiological data 310
We confirmed that neuronal recordings were done in the STN, based on the depth reading of 311 the microdrive during the recording sessions and on the location of recording tracks visible in the Nissl 312 and MAP2 immunolabeled tissue sections. The recordings were further analyzed if the signal to noise 313 ratio was at least two. We sorted spikes off-line with a waveform matching algorithm, followed by 314 principal component analysis (Spike2), and constructed inter-spike interval (ISI) distribution histograms 315 for quality control. Only single-unit recordings were included in the analysis. Custom-written Matlab 316 (Mathworks, Natick, MA) algorithms were used for the rest of the analysis, which was performed using 317 ISI data. 318
Several parameters of neuronal firing were considered in our analysis, including the mean firing 319 rate (number of spikes/s); the coefficient of variation of the ISIs (ISI CV, standard deviation/mean); burst 320 characteristics and power spectra. To detect bursts, we used the method described by Legendy and 321
Salcman (Legendy and Salcman 1985; Wichmann and Soares 2006), with a 'surprise' value of 3. In the 322 identified bursts we calculated the mean intraburst firing rate, the maximal increase of firing within a 323 burst (MIFB, i.e., the maximal burst firing rate, divided by the mean firing rate of the neuron), the 324 proportion of time that the cell spent in burst discharges, and the proportion of spikes in bursts 325
(compared to the total number of spikes). We also calculated the firing rate during burst and non-burst 326 segments, as well as the proportion of time and spikes that were not part of bursts. Non-bursting data 327 segments were generated by removing all ISIs identified as belonging to bursts from the original data 328 stream. Bursts were classified as "pause-burst sequences" if the ISI immediately preceding the burst 329 was at least three times longer than the mean ISI of the neuron's discharge. Some of these sequences 330 may represent rebound bursts, as described in in vitro experiments (e. g. To analyze the effects of the drug infusions, a period of 60 s before the start of the drug infusion 345 was used as a "control" (baseline) segment. The "drug effect" segment was defined as starting with the 346 drug injection and lasting up to 300 s afterwards. The duration of the "effect" segment was 263 ± 58 s 347 (mean ± SD). If either the baseline or the drug effect segment contained fewer than 200 ISIs, the 348 experiment was not further considered. are means ± SD) and terminals (16.2 ± 7.1%). A smaller proportion of D1 receptor-immunopositive 375 elements was accounted for by postsynaptic dendrites (7.3 ± 0.9%), myelinated axons (13.6 ± 16%) or 376 glial processes (9.2 ± 4.9%). Micrographs of representative D1-labeled elements are depicted in fig. 1 (A  377 and B) and the summary of quantitative data about their relative distribution is shown in fig. 2A . Of all 378 D1 receptor-immunoreactive terminals that formed clearly identifiable synaptic contacts (n = 46), 65.4 ± 379 7.6% formed asymmetric, putatively glutamatergic, synapses, while 34.6 ± 7.6% formed symmetric, 380 putatively GABAergic, synapses ( fig. 2B) . 381
Like D1 receptors, D5 receptor immunoperoxidase labeling was also commonly seen in pre-382 terminal axons (31.1 ± 17.5%) and terminals (11.6 ± 1.8%, fig. 2A ). Of the terminals whose synapse could 383 be clearly identified (n = 45), 58.7 ± 25.0% formed asymmetric synapses and 41.3 ± 25.0% formed 384 symmetric synapses ( fig. 1C, 2B ). The proportion of D5 receptor-immunopositive dendritic 385 (postsynaptic) elements was larger than that labeled for D1 receptors (32.8 ± 10.6%, fig. 1D, 2A) . D5 386 receptor immunopositive myelinated axons were also found (15.7 ± 15.4%), while glial processes were 387 less abundant (8.8 ± 7.4%). 388 D2 receptor immunoperoxidase labeling was also primarily seen in presynaptic elements, but in 389 contrast to D1 and D5 receptors, the largest proportion of positive elements were terminals (50.4 ± 390 15.7%), followed by pre-terminal axons (15.8 ± 5.1%). Dendrites accounted for 21.5 ± 4.8% of D2 391 receptor-immunopositive elements, while only scarce labeling was found in myelinated axons (3.2 ± 392 2.3%) and glial processes (8.9 ± 7%, fig. 2A ). Of the terminals whose synapse could be clearly identified 393 (n=84), 82.7 ± 15.3% formed asymmetric synapses, while fewer (17.3 ± 15.3%) formed symmetric, 394 putatively GABAergic synapses (figs. 1E and F, 2B). 395
To determine if the preferential expression of the different dopamine receptor subtypes in 396 terminals forming asymmetric over symmetric synapses ( fig. 2B ) was merely due to the relative 397 abundance of these two types of terminals in the monkey STN, we quantified the total number of 398 terminals forming symmetric or asymmetric synapses in the STN of 3 normal monkeys, and found that 399 76.7 ± 27.7% of terminals in the STN form symmetric synapses, while 32.3 ± 7.0% form asymmetric 400 synapses ( fig. 2C ). This finding indicates that the abundance of dopamine receptor labeling at terminals 401 forming asymmetric synapses was not due to an overall high incidence of this type of terminals. 
Effects of dopamine receptor agonists on the firing rates and patterns of STN neurons 425
We recorded the activity of STN neurons before, during, and after local administration of the 426 D1-like receptor agonist SKF82958 (3 μg/μl), the D2-like receptor agonist quinpirole (5 μg/μl) or aCSF as 427 control. All injections were delivered at a rate of 0.2 μl/min for a total volume of 0.4 μl. 428
The final analysis included data from 14 cells that were exposed to control infusions of aCSF 429 (cells from normal and MPTP-treated animals were pooled together); 32 cells that were exposed to 430 SKF82958 (13 and 19 neurons from normal and MPTP-treated animals, respectively) and 28 cells that 431 were tested in the presence of quinpirole (17 and 11 from normal and MPTP-treated animals, 432 respectively). The effects of these compounds on the firing rate and other firing parameters of STN 433 neurons were determined by comparing each drug-treated group of cells (D1-and D2-like receptor 434 agonist infusions in normal and in MPTP-treated monkeys) against the aCSF group. 435
The D1-like receptor agonist SKF82958 significantly reduced the mean firing rate of STN neurons 436 compared to the effects of aCSF, in both normal and MPTP-treated animals (p=0.029 and 0.026 for 437 normal and MPTP-treated monkeys respectively, fig. 3A ). The reductions in the mean firing rate by 438 SKF82958 were observed not only during the non-bursting segment (p=0.014 and p=0.019 for normal 439 and MPTP-treated monkeys respectively, Mann-Whitney test, fig. 3B ), but also during the bursting 440 episodes of neuronal activity (p=0.038 and p=0.011 for normal and MPTP-treated animals respectively, 441 fig. 4B ). In normal monkeys, SKF82958 also increased the variability of firing of STN neurons (as 442 measured with the CV; p=0.019, fig. 3C ). 443 SKF82958 raised the MIFB values of STN neurons in normal monkeys (p=0.014 compared to 444 aCSF, fig. 4A ). Also, after SKF82958 injections, STN neurons in normal and MPTP-treated animals 445
showed an increased proportion of pause-burst sequences, compared to cells recorded after aCSF 446 injections (p=0.002 for normal and p=0.016 for MPTP-treated, fig. 4C ). Finally, the proportion of pause-447 burst sequences that also fulfilled the criteria for ILBs, was increased after D1-like receptor treatment 448 for normal and MPTP-treated STN neurons (p=0.003 and p=0.008 in normal and MPTP-treated cases 449 respectively, fig. 4D ). 450
The administration of the D2-like receptor agonist quinpirole did not significantly affect the 451 mean firing rate or CV of STN neurons ( fig. 3) . However, quinpirole increased the proportion of pause-452 burst sequences, including those classified as ILBs (p=0.036 and p=0.033, respectively, fig. 4C and D) . In 453 MPTP-treated monkeys, the effects of quinpirole on the firing rates and CV of STN neurons were highly 454 variable, eliciting either increases or decreases of individual neurons activity. In the aggregate, these 455 effects were not significant ( fig. 3) . As in normal monkeys, the proportion of pause-burst sequences in 456 STN neurons after D2-like receptor activation in MPTP-treated monkeys was higher than after aCSF, but 457 the difference did not reach statistical significance in this group (p=0.058, fig. 4C ). In contrast to the 458 effect of quinpirole in normal monkeys, the D2-like receptor agonist did not change the proportion of 459
ILBs preceded by a pause in MPTP-treated monkeys ( fig. 4D) . 460
461
DISCUSSION 462
Our anatomical study demonstrates that D1, D5 and D2 dopamine receptors are preferentially 463 expressed presynaptically, on pre-terminal axons and putative glutamatergic terminals in the monkey 464 STN. Although presynaptic labeling predominated for the three receptor subtypes, postsynaptic 465 dendritic expression was also found, most particularly for D5 receptors. We also found that the 466 activation of D1-like receptors in the monkey STN decreased the neuronal firing rate and increased the 467 variability of firing, primarily by increasing the intra-burst firing rate and the proportions of bursts that 468 were preceded by a pause. In normal monkeys, the proportions of such pause-burst sequences and 469 specifically that of ILBs preceded by a pause were also increased after activation of D2-like receptors. 470
471
Changes in firing characteristics of STN neurons after MPTP treatment 472
Our data showed that the burst firing pattern of STN neurons changed in MPTP-treated 473 parkinsonian monkeys. Thus, there was an increase in the maximal intra-burst rate, and in the 474 proportion of ILBs preceded by pauses. These specific parameters were previously found to be the best 475 found that the proportion of STN neurons with low frequency oscillations was higher in MPTP-treated 481 monkeys than in normal animals, as reported previously (Bergman et al. 1994) . 482
The differences in these parameters between our study and previously reported studies are 483 
Overall distribution of dopamine receptors in STN 492
We found most labeling for D1, D2 and D5 receptors on presynaptic elements (pre-terminal 493 axons and terminals). Similarly, our previous studies in monkeys showed that D1, D2 and D5 receptors 494 in the internal segment of the globus pallidus (GPi), SNr and GPe were mostly located in pre ratio of immunopositive pre-terminal axons/terminals was higher for D1 than for D2 receptors in the 512 monkey STN, suggesting that the pre-synaptic regulation of transmission via activation of axonal 513 dopamine receptors could be more prevalent for D1 than for D2 receptors in the monkey STN. 514
We also found terminal labeling for the different dopamine receptors in the monkey STN, 515 preferentially in putative glutamatergic terminals forming asymmetric synapses. Because our findings 516 indicate that the STN contained at least twice more terminals forming symmetric than asymmetric 517 synapses ( fig. 2C ), this differential expression of dopamine receptors between putative excitatory and 518 inhibitory terminals suggest a preferential dopamine-mediated pre-synaptic regulation of glutamatergic 519 over GABAergic transmission in the primate STN. 520
The rest of the immunolabeling was found in post-synaptic dendrites (especially prevalent in D5 521 receptor-immunolabeled material, as discussed below), in some glial processes and in myelinated axons. 
